All Wales Advice on SGLT-2 Inhibitors in Type 2 Diabetes and Cardiovascular Disease (Consultation)

This draft guidance includes a comprehensive review of the evidence for SGLT-2 inhibitor use in type 2 diabetes mellitus in relation to cardiovascular outcomes and provides recommendations on the role of SGLT-2 inhibitors in this patient population.

All Wales Medicines Strategy Group